We started Beat the Odds because one decision, where a patient is treated, too often gets made by geography and cost rather than by medicine. So for Sarcoma Awareness Month we wanted to do something straightforward: walk through what the research actually says, without slogans, and look at what the studies mean for a family sitting in a waiting room right now.
Here are four things the evidence is clear about.
The clock starts late, because sarcoma is easy to miss
Sarcoma rarely announces itself. It shows up as a lump that does not hurt, a pulled muscle that will not heal, or growing pains in a teenager, and a 2020 systematic review in ESMO Open, pulling together decades of data on how long diagnosis actually takes, found a range that is genuinely staggering: for soft-tissue sarcomas, the total interval from first symptom to diagnosis ran anywhere from about a month to more than eleven years across the studies reviewed.¹
The same review found that at non-specialist centers imaging was read as normal in a meaningful share of cancers that were, in fact, malignant, while specialist sarcoma centers correctly identified the malignancy in about 94% of cases.¹ This is not about blame so much as exposure, because a general radiologist may see one sarcoma in years while a sarcoma center sees them every week, and a second look from someone who specializes in these tumors is often what closes the gap between a missed lump and a caught one.
At specialist sarcoma centers, about 94% of malignancies were correctly identified. At non-specialist centers, many were read as normal.
Even the diagnosis itself can change under an expert microscope
Here is a fact most families never hear: the pathology report, the document that names your exact tumor and drives your entire treatment plan, is not always final. In a prospective study of 366 sarcoma patients in France, published in BMC Cancer, only 54% of cases fully agreed with the original diagnosis once an expert sarcoma pathologist reviewed them, about 19% were reclassified as a different tumor type entirely, and in total more than 45% of first diagnoses were modified on expert review.²
Change the diagnosis and you can change the whole treatment, because a different subtype can mean different chemotherapy, a different surgery, and different odds, which is exactly why sarcoma specialists insist on central pathology review. When nearly half of first-pass diagnoses are revised by an expert, a second reading is not second-guessing; it is standard of care.
More than 45% of first sarcoma diagnoses were modified once an expert pathologist reviewed them.
The first surgery is the one that counts
Of everything in this article, this may be the point we most want families to sit with, because in sarcoma the first operation is frequently the best, and sometimes the only, real chance to remove the tumor cleanly.
When a sarcoma is mistaken for a harmless cyst or lipoma and shelled out by a surgeon who did not know it was cancer, the field calls it an unplanned excision, or a whoops procedure, and it sounds minor but is anything but. In a study of 451 patients in Cancer Medicine, more than half of these unplanned excisions left cancer behind at the site, tumor that then had to be chased with a second, bigger operation, and the survival gap was stark: among extremity and trunk sarcomas, five-year disease-specific survival was 68.8% when residual tumor was found, against 92% when it was not.³ Same disease, different first surgeon.
The other side of that coin is just as important, because done right, modern sarcoma surgery is remarkably limb-preserving. A 2020 meta-analysis in the Journal of Bone Oncology covering nearly 2,900 osteosarcoma patients found that limb-salvage surgery was associated with roughly double the odds of five-year survival compared with amputation, and without a significant increase in the cancer coming back.⁴ Saving the limb and saving the life are not in tension, provided the operation is done by a team that does it often.
Five-year survival was 68.8% when the first surgery left tumor behind, versus 92% when it did not.
Where you are treated changes whether you live
Put those first three findings together and you arrive at the largest one of all: specialist sarcoma centers produce better survival, and the effect is not subtle.
The clearest evidence comes from France’s NETSARC network, a nationwide system of reference sarcoma centers. In a study of 35,784 patients published in Annals of Oncology, having surgery at a reference center was associated with a hazard ratio of 0.681 for overall survival, a meaningfully lower risk of death, alongside better local control and relapse-free survival.⁵ That is a nationwide dataset showing that the address on your surgery reduced your risk of dying.
It holds up in United States data too, where a 2026 study in Cancer analyzing hospital volume found five-year overall survival of 64.8% at high-volume hospitals against 60.0% at low-volume ones, with the benefit even larger for adults.⁶ The common thread across all of these studies is volume and specialization: teams that treat a great deal of sarcoma, in one coordinated place, simply get better results.
Across 35,784 patients, surgery at a reference sarcoma center carried a hazard ratio of 0.681 for death.
The thread that ties it together, and where distance comes in
Read those four findings in order and a single story emerges: sarcoma is easy to miss, easy to misclassify, and easy to operate on incorrectly, and the one thing that consistently protects against all three is getting to a specialist sarcoma center. The evidence for that is about as strong as this rare a cancer ever produces.
Which raises the obvious question. If specialist centers are that much better, why doesn’t everyone simply go? Because there are only about twenty of them in the entire country, and getting there costs money, gas, flights, hotels, that most families do not have sitting in an account.
When researchers looked at whether distance itself harms patients, they found something telling. In a nationwide study of 34,528 soft-tissue sarcoma patients in PLOS One, the ones who traveled farther actually survived longer, not because travel is good for you but because the people who traveled were the ones who reached academic specialist centers.⁷ Close to home, only 37% of patients received care at an academic center; among those who traveled more than a hundred miles, 75.9% did. The distance was never the medicine. The destination was.
You see the same pattern in retroperitoneal sarcoma, one of the hardest kinds to operate on, where a study of 2,599 patients in the World Journal of Surgical Oncology found that patients who traveled far to a high-volume center had lower 30-day surgical mortality, 1.2% against 2.8%, and better five-year survival, 63% against 53%, than those who stayed close to a low-volume one.⁸ Overcoming the travel burden, the authors wrote, was associated with improved survival.
So distance is not a small logistical footnote to sarcoma care; for a great many families it is the deciding factor in whether they can reach the kind of center every study here points toward. That is the gap we exist to close. Beat the Odds funds the travel, lodging, and gas that get sarcoma patients to specialist centers, so that the address of the hospital treating you is not decided by the balance in a checking account.
Close to home, 37% of patients reached an academic center. Past 100 miles, 75.9% did.
Distance should not decide who survives sarcoma. The research is clear about where patients do best, and we help them get there.